Strategies for enzyme/prodrug cancer therapyGUANO XU; MCLEOD, Howard L.Clinical cancer research. 2001, Vol 7, Num 11, pp 3314-3324, issn 1078-0432Article

Methotrexate pharmacogenetics : The first step toward individualized therapy in rheumatoid arthritisRANGANATHAN, Prabha; MCLEOD, Howard L.Arthritis and rheumatism. 2006, Vol 54, Num 5, pp 1366-1377, issn 0004-3591, 12 p.Article

Cancer pharmacogenomics: SNPs, Chips, and the individual patientMCLEOD, Howard L; JINSHENG YU.Cancer investigation. 2003, Vol 21, Num 4, pp 630-640, issn 0735-7907, 11 p.Article

Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical applicationLEE, Soo-Youn; MCLEOD, Howard L.Journal of pathology (Print). 2011, Vol 223, Num 1, pp 15-27, issn 0022-3417, 13 p.Article

Economic Opportunities and Challenges for PharmacogenomicsDEVERKA, Patricia A; VERNON, John; MCLEOD, Howard L et al.Annual review of pharmacology and toxicology (Print). 2010, Vol 50, pp 423-437, issn 0362-1642, 15 p.Article

Should DPD analysis be required prior to prescribing fluoropyrimidines?YEN, Jane L; MCLEOD, Howard L.European journal of cancer (1990). 2007, Vol 43, Num 6, pp 1011-1016, issn 0959-8049, 6 p.Article

Pharmacogenomics - drug disposition, drug targets, and side effectsEVANS, William E; MCLEOD, Howard L.The New England journal of medicine. 2003, Vol 348, Num 6, pp 538-549, issn 0028-4793, 12 p.Article

Disulfiram-mediated inhibition of NF-κB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell linesWANG, Weiguang; MCLEOD, Howard L; CASSIDY, James et al.International journal of cancer. 2003, Vol 104, Num 4, pp 504-511, issn 0020-7136, 8 p.Article

Genomics and Drug ResponseLIEWEI WANG; MCLEOD, Howard L; WEINSHILBOUM, Richard M et al.The New England journal of medicine. 2011, Vol 364, Num 12, pp 1144-1153, issn 0028-4793, 10 p.Article

Pharmacogenetic analysis of clinically relevant genetic polymorphismsMCLEOD, Howard L.Clinical infectious diseases. 2005, Vol 41, pp S449-S452, issn 1058-4838, SUP7Conference Paper

Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometryWEIYING HOU; WATTERS, James W; MCLEOD, Howard L et al.Journal of chromatography. B. 2004, Vol 804, Num 2, pp 263-267, issn 1570-0232, 5 p.Article

Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in OncologyHERTZ, Daniel L; McLEOD, Howard L.Clinical cancer research (Print). 2014, Vol 20, Num 10, pp 2530-2540, issn 1078-0432, 11 p.Article

CANCER PHARMACOGENOMICS : DNA GENOTYPING AND GENE EXPRESSION PROFILING TO IDENTIFY MOLECULAR DETERMINANTS OF CHEMOSENSITIVITYAUMAN, J. Todd; MCLEOD, Howard L.Drug metabolism reviews (Softcover ed.). 2008, Vol 40, Num 2, pp 303-315, issn 0360-2532, 13 p.Article

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?YEN-REVOLLO, Jane L; GOLDBERG, Richard M; MCLEOD, Howard L et al.Clinical cancer research. 2008, Vol 14, Num 1, pp 8-13, issn 1078-0432, 6 p.Article

Ferredoxin reductase: Pharmacogenomic assessment in colorectal cancerJINSHENG YU; MARSH, Sharon; AHLUWALIA, Ranjeet et al.Cancer research (Baltimore). 2003, Vol 63, Num 19, pp 6170-6173, issn 0008-5472, 4 p.Article

Genetic basis of drug metabolismMA, Margaret K; WOO, Michael H; MCLEOD, Howard L et al.American journal of health-system pharmacy. 2002, Vol 59, Num 21, pp 2061-2069, issn 1079-2082, 9 p.Article

Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancerMARSH, Sharon; MCKAY, Judith A; CASSIDY, James et al.International journal of oncology. 2001, Vol 19, Num 2, pp 383-386, issn 1019-6439Article

Pharmacogenomics : from bedside to clinical practiceMARSH, Sharon; MCLEOD, Howard L.Human molecular genetics (Print). 2006, Vol 15, issn 0964-6906, R89-R93, NSArticle

Pharmacogenetic influences on treatment response and toxicity in colorectal cancerTAN, Benjamin R; MCLEOD, Howard L.Seminars in oncology. 2005, Vol 32, Num 1, pp 113-119, issn 0093-7754, 7 p.Article

Pharmacogenomic dissection of resistance to thymidylate synthase inhibitorsWEIGUANG WANG; MARSH, Sharon; CASSIDY, James et al.Cancer research (Baltimore). 2001, Vol 61, Num 14, pp 5505-5510, issn 0008-5472Article

Genomics: Applications in mechanism elucidationGRESHAM, Venita; MCLEOD, Howard L.Advanced drug delivery reviews. 2009, Vol 61, Num 5, pp 369-374, issn 0169-409X, 6 p.Article

Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecanGUANG XU; WANGHAI ZHANG; MA, Margaret K et al.Clinical cancer research. 2002, Vol 8, Num 8, pp 2605-2611, issn 1078-0432Article

Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasmsWANGHAI ZHANG; HART, John; MCLEOD, Howard L et al.American journal of clinical pathology. 2005, Vol 124, Num 1, pp 11-19, issn 0002-9173, 9 p.Article

A novel duplication type of CYP2A6 gene in African-American populationFUKAMI, Tatsuki; NAKAJIMA, Miki; YAMANAKA, Hiroyuki et al.Drug metabolism and disposition. 2007, Vol 35, Num 4, pp 515-520, issn 0090-9556, 6 p.Article

Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex : thymidylate synthase dependent and independent networksWEIGUANG WANG; MCLEOD, Howard L; CASSIDY, James et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 6, pp 839-845, issn 0344-5704, 7 p.Article